Inex/Hana licensing deal
Executive Summary
Inex signed a Letter of Intent to license three chemotherapy pipeline products to Hana Biosciences, company announces. The oncologics include Marqibo (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan). Inex/Enzon's Marqibo was deemed "not approvable" Jan. 14 following an Oncologic Drugs Advisory Committee recommendation against accelerated approval for third-line non-Hodgkin's lymphoma (1"The Pink Sheet" Dec. 6, 2004, p. 20). Under the deal, Hana will develop and commercialize the products and pay Inex $11.5 mil. in upfront payments. Inex also could receive $30.5 mil. in milestone payments...
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.